Genelux Corp. (GNLX): Price and Financial Metrics

Genelux Corp. (GNLX): $6.43

0.41 (+6.81%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

D

Add GNLX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#319 of 365

in industry

GNLX Price/Volume Stats

Current price $6.43 52-week high $40.98
Prev. close $6.02 52-week low $5.67
Day low $5.90 Volume 102,500
Day high $6.44 Avg. volume 118,049
50-day MA $8.08 Dividend yield N/A
200-day MA $17.91 Market Cap 171.80M

GNLX Stock Price Chart Interactive Chart >

GNLX POWR Grades

  • Sentiment is the dimension where GNLX ranks best; there it ranks ahead of 69.11% of US stocks.
  • GNLX's strongest trending metric is Quality; it's been moving down over the last 26 weeks.
  • GNLX ranks lowest in Momentum; there it ranks in the 10th percentile.

GNLX Stock Summary

  • GENELUX CORP's stock had its IPO on January 26, 2023, making it an older stock than just 0.15% of US equities in our set.
  • With a price/sales ratio of 1,595.2, GENELUX CORP has a higher such ratio than 99.53% of stocks in our set.
  • Revenue growth over the past 12 months for GENELUX CORP comes in at -97.85%, a number that bests merely 0.89% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to GENELUX CORP are IPWR, VERU, AIP, PACB, and GANX.
  • Visit GNLX's SEC page to see the company's official filings. To visit the company's web site, go to www.genelux.com.

GNLX Valuation Summary

  • GNLX's price/sales ratio is 1572.7; this is 37345.24% higher than that of the median Healthcare stock.
  • Over the past 48 weeks, GNLX's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for GNLX.

Stock Date P/S P/B P/E EV/EBIT
GNLX 2023-12-29 1572.7 15.6 -15.0 -14.1
GNLX 2023-12-28 1817.6 18.0 -17.3 -16.4
GNLX 2023-12-27 1655.9 16.4 -15.7 -14.9
GNLX 2023-12-26 1686.1 16.7 -16.0 -15.2
GNLX 2023-12-22 1574.8 15.6 -15.0 -14.1
GNLX 2023-12-21 1568.1 15.5 -14.9 -14.0


GNLX Latest News Stream


Event/Time News Detail
Loading, please wait...

GNLX Latest Social Stream


Loading social stream, please wait...

View Full GNLX Social Stream

Latest GNLX News From Around the Web

Below are the latest news stories about GENELUX CORP that investors may wish to consider to help them evaluate GNLX as an investment opportunity.

Insider Sell Alert: Director James Tyree Offloads 9,000 Shares of Genelux Corp (GNLX)

In the realm of stock market movements, insider trading activity is often a significant indicator for investors.

Yahoo | December 15, 2023

Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer

- Pivotal Phase 3 Study of Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer Initiated in September 2022 - - Phase 2 Trial of Olvi-Vec- Demonstrated Clinical Reversal of Platinum Resistance and Refractoriness and Met Primary Endpoint of Objective Response Rate with Durable Responses - WESTLAKE VILLAGE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the United States Food and Drug Administrat

Yahoo | November 27, 2023

Genelux Corporation (NASDAQ:GNLX) most popular amongst retail investors who own 57%, insiders hold 25%

Key Insights Significant control over Genelux by retail investors implies that the general public has more power to...

Yahoo | November 17, 2023

Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates

- Expanded executive team as Lourie Zak appointed Chief Financial Officer - - Extended clinical focus on systemic administration in small cell lung cancer - - $29.9 million in cash and equivalents - WESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter of 2023 and provided general business updates. “The third quarter was highlighted by continued expansi

Yahoo | November 14, 2023

12 Best Performing Biotech Stocks in 2023

In this piece, we will take a look at the 12 best performing biotechnology stocks in 2023. If you want to skip our introduction to the biotechnology industry and some top players, then check out 5 Best Performing Biotech Stocks in 2023. Biotechnology is one of the hottest industries these days and one that has […]

Yahoo | October 20, 2023

Read More 'GNLX' Stories Here

GNLX Price Returns

1-mo -19.32%
3-mo -54.10%
6-mo -73.74%
1-year -78.56%
3-year N/A
5-year N/A
YTD -54.10%
2023 N/A
2022 N/A
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!